JP2008501034A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008501034A5 JP2008501034A5 JP2007515456A JP2007515456A JP2008501034A5 JP 2008501034 A5 JP2008501034 A5 JP 2008501034A5 JP 2007515456 A JP2007515456 A JP 2007515456A JP 2007515456 A JP2007515456 A JP 2007515456A JP 2008501034 A5 JP2008501034 A5 JP 2008501034A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- buffer system
- posaconazole
- agent
- microns
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000009472 formulation Methods 0.000 claims 22
- 239000000203 mixture Substances 0.000 claims 22
- 239000007853 buffer solution Substances 0.000 claims 6
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 claims 5
- 229960001589 posaconazole Drugs 0.000 claims 5
- 150000003904 phospholipids Chemical class 0.000 claims 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 3
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims 3
- 229960003942 amphotericin b Drugs 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 239000011814 protection agent Substances 0.000 claims 3
- 239000001488 sodium phosphate Substances 0.000 claims 3
- WTJKGGKOPKCXLL-VYOBOKEXSA-N 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC WTJKGGKOPKCXLL-VYOBOKEXSA-N 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 2
- 235000011008 sodium phosphates Nutrition 0.000 claims 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims 1
- 235000011130 ammonium sulphate Nutrition 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000002111 antiemetic agent Substances 0.000 claims 1
- 229940125683 antiemetic agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 229940009976 deoxycholate Drugs 0.000 claims 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 1
- 229910000397 disodium phosphate Inorganic materials 0.000 claims 1
- 235000019800 disodium phosphate Nutrition 0.000 claims 1
- 229960004413 flucytosine Drugs 0.000 claims 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 229960002722 terbinafine Drugs 0.000 claims 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 claims 1
- 239000008215 water for injection Substances 0.000 claims 1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57512604P | 2004-05-28 | 2004-05-28 | |
PCT/US2005/018945 WO2005117831A1 (en) | 2004-05-28 | 2005-05-27 | Injectable pharmaceutical suspension comprising posaconazole |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008501034A JP2008501034A (ja) | 2008-01-17 |
JP2008501034A5 true JP2008501034A5 (US07981874-20110719-C00313.png) | 2008-07-03 |
Family
ID=34971355
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007515456A Withdrawn JP2008501034A (ja) | 2004-05-28 | 2005-05-27 | ポサコナゾールを含む注射用薬学的懸濁液 |
Country Status (15)
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060009469A1 (en) * | 2004-05-28 | 2006-01-12 | Leonore Witchey-Lakshmanan | Particulate-stabilized injectable pharmacutical compositions of posaconazole |
CA2651726C (en) | 2006-05-12 | 2015-12-15 | Pharmacon - Forschung Und Beratung Gmbh | Use of combination preparations, comprising antimycotics |
EP2130540A1 (en) * | 2008-06-02 | 2009-12-09 | Sandoz AG | Pharmaceutical compositions containing a crystalline form of posaconazole |
EP2141159A1 (en) | 2008-07-03 | 2010-01-06 | Sandoz AG | A Crystalline form of posaconazole |
EP2451805A1 (en) | 2009-07-09 | 2012-05-16 | Sandoz AG | A crystalline form of posaconazole |
CN102906087B (zh) | 2010-05-19 | 2016-03-23 | 桑多斯股份公司 | 制备手性三唑酮的方法 |
RU2585683C2 (ru) | 2010-05-19 | 2016-06-10 | Сандоз Аг | Очистка позаконазола и промежуточных продуктов для синтеза позаконазола |
RU2580318C2 (ru) | 2010-05-19 | 2016-04-10 | Сандоз Аг | Получение промежуточных продуктов для синтеза позаконазола |
EP2571847B1 (en) | 2010-05-19 | 2016-09-21 | Sandoz AG | Process for the preparation of chiral hydrazides |
ES2893444T3 (es) * | 2010-06-29 | 2022-02-09 | Merck Sharp & Dohme | Formulaciones de posaconazol en solución intravenosa estabilizadas mediante beta-ciclodextrina sustituida |
CA2838051C (en) | 2011-06-16 | 2019-09-24 | Sandoz Ag | Process for the preparation of a chiral compound |
CN103284959B (zh) * | 2012-02-22 | 2015-06-03 | 重庆圣华曦药业股份有限公司 | 泊沙康唑冻干粉针剂及制备方法 |
CN102755628B (zh) * | 2012-07-16 | 2013-10-23 | 中国科学院微生物研究所 | 一种抗真菌的药物组合物 |
CN102805731B (zh) * | 2012-08-22 | 2014-04-30 | 北京莱瑞森医药科技有限公司 | 泊沙康唑干混悬剂及其制备方法 |
CN105030668B (zh) * | 2015-06-26 | 2018-03-27 | 济川药业集团有限公司 | 泊沙康唑口服混悬剂及其制备方法 |
CN106333925B (zh) * | 2015-07-10 | 2019-06-18 | 上海美悦生物科技发展有限公司 | 一种泊沙康唑液体混悬剂及其制备方法 |
CN105997872B (zh) * | 2016-07-08 | 2019-02-19 | 河南省立眼科医院 | 一种含有泊沙康唑的眼用纳米胶束抗真菌溶液 |
CA3056919A1 (en) * | 2017-03-26 | 2018-10-04 | Vivi Robyn Stafford | Method of treatment of skin conditions of eye lids |
CN111093373A (zh) * | 2017-04-12 | 2020-05-01 | V·J·班格万丁 | 组合物、包装的药物和使用泊沙康唑用于敏化抗性肿瘤的方法 |
CN110507609B (zh) * | 2018-05-21 | 2021-09-17 | 上海医药工业研究院 | 泊沙康唑口服混悬剂的制备方法 |
CN111514146A (zh) * | 2020-04-28 | 2020-08-11 | 山西振东泰盛制药有限公司 | 含有泊沙康唑的药物组合物 |
CN113933131B (zh) * | 2021-09-24 | 2024-01-26 | 合肥天一生物技术研究所有限责任公司 | 一种阴道微生物荧光染色液 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5091188A (en) * | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
AU2002257104B2 (en) * | 2001-04-03 | 2006-02-09 | Merck Sharp & Dohme Corp. | Antifungal composition with enhanced bioavailability |
-
2005
- 2005-05-27 KR KR1020067024996A patent/KR20070027564A/ko not_active Application Discontinuation
- 2005-05-27 AR ARP050102203A patent/AR049063A1/es not_active Application Discontinuation
- 2005-05-27 TW TW094117524A patent/TWI290051B/zh not_active IP Right Cessation
- 2005-05-27 WO PCT/US2005/018945 patent/WO2005117831A1/en active Application Filing
- 2005-05-27 PE PE2005000599A patent/PE20060291A1/es not_active Application Discontinuation
- 2005-05-27 JP JP2007515456A patent/JP2008501034A/ja not_active Withdrawn
- 2005-05-27 EP EP05755118A patent/EP1761247A1/en not_active Withdrawn
- 2005-05-27 RU RU2006146555/15A patent/RU2006146555A/ru not_active Application Discontinuation
- 2005-05-27 CA CA002567803A patent/CA2567803A1/en not_active Abandoned
- 2005-05-27 MX MXPA06013886A patent/MXPA06013886A/es unknown
- 2005-05-27 AU AU2005249502A patent/AU2005249502A1/en not_active Abandoned
- 2005-05-27 CN CNA2005800248542A patent/CN1988887A/zh active Pending
-
2006
- 2006-11-27 IL IL179627A patent/IL179627A0/en unknown
- 2006-11-27 ZA ZA200609890A patent/ZA200609890B/xx unknown
- 2006-12-22 NO NO20066005A patent/NO20066005L/no not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008501034A5 (US07981874-20110719-C00313.png) | ||
JP5681693B2 (ja) | 動物における障害を治療および予防するための薬剤組成物の経粘膜投与 | |
McShane et al. | Ciprofloxacin dry powder for inhalation (ciprofloxacin DPI): technical design and features of an efficient drug–device combination | |
EP3067046B1 (en) | Lipid-based compositions of antiinfectives for treating pulmonary infections | |
US5648399A (en) | Liquid polymer composition and method of use | |
Pastor et al. | Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis | |
US5160737A (en) | Liquid polymer composition, and method of use | |
ES2875584T3 (es) | Formulación para inhalación líquida que comprende RPL554 | |
EA200501001A1 (ru) | Фармацевтический состав с нерастворимым активным агентом | |
ES2525163T3 (es) | Método para preparar composiciones farmacéuticas pretendidas para administración oral que comprenden uno o más ingredientes activos y las composiciones que comprenden los mismos | |
CA2467611A1 (en) | Azithromycin dosage forms with reduced side effects | |
Zillen et al. | Natural and bioinspired excipients for dry powder inhalation formulations | |
JP2015517522A (ja) | 実質的に水不溶性の薬物の送達のための医薬組成物 | |
CZ299348B6 (cs) | Aerosolový prostredek | |
García et al. | Ibuprofen, a traditional drug that may impact the course of COVID-19 new effective formulation in nebulizable solution | |
ES2928399T3 (es) | Composición farmacéutica bactericida que comprende ibuprofeno | |
US20220287996A1 (en) | Methods and compositions for treating edema refractory to oral diuretics | |
JP2007091686A (ja) | ヒノキチオールを含有するナノ粒子 | |
US20220151944A1 (en) | Fluorouracil-containing formulations | |
US20210077449A1 (en) | Formulations Having Anti-inflammatory Activity and Antimicrobial Activity Against Gram-Positive Bacteria | |
JPH0617300B2 (ja) | 歯周疾患治療用組成物 | |
ES2883144T3 (es) | Efectos sinérgicos que incrementan los efectos antimicrobianos de los lípidos | |
US20220152092A1 (en) | Microbial removal | |
TW202227104A (zh) | 預防感染之組合物 | |
JP2006518719A (ja) | ヘルペスの治療のためのpvp−ヨウ素リポソームの使用 |